MannKind Corporation MNKD

MNKD Company Overview

MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases. The company operates primarily within the biopharmaceutical and drug-device combination industries, leveraging proprietary inhalation technologies to deliver medicines via the pulmonary route. MannKind’s business is centered on improving drug delivery efficiency, patient convenience, and therapeutic outcomes, particularly for chronic conditions requiring frequent dosing.

The company’s core commercial product is Afrezza, a rapid-acting inhaled insulin for adults with diabetes, which represents its primary revenue driver. MannKind also generates revenue through manufacturing services and collaborative agreements using its proprietary Technosphere technology platform. Founded in 1991 by Alfred E. Mann, the company initially focused on medical device innovation before evolving into a biopharmaceutical firm, culminating in the FDA approval of Afrezza in 2014 and subsequent restructuring to focus on pulmonary drug delivery.